The Effect of Prophylactic TPO Combined with BMS-IMRT to Esophageal Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
Esophageal CancerIntensity-modulated Radiation TherapyConcurrent ChemoradiotherapyThrombocytopenia
Interventions
DRUG

rhTPO

"Standard treatment options:~Radiotherapy: 95% planning target volume (planning target volume,PTV) ≥45Gy(without simultaneous boost).~Concurrent chemotherapy:~Weekly regimen: paclitaxel 50mg/m2 d1, nedaplatin/cisplatin 25 mg/m2d1, a total of 5 cycles.~Three weeks regimen: paclitaxel 135-175mg/m2 d1, nedaplatin/cisplatin 80mg/m2, a total of 2 cycles.~The active bone marrow was determined by magnetic resonance(magnetic resonance,MR), and the dose limits are: V5\<95%,V10\<85%,V20\<60%,V30\<40%;95%PTV\>45Gy.~rhTPO,15000U ih. qw(during the radiotherapy course)"

Trial Locations (1)

100021

Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing

All Listed Sponsors
collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

JIANYANG WANG

OTHER